SCHEMBL6356796

SCHEMBL6356796

C=C1C=CC(=O)N1CC1CCC(C(=O)NCCCCC(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 4/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 2/20 0.37
EPHX2 P34913 1/20 0.36
HPGD P15428 2/20 0.35
MAPT P10636 1/20 0.35
TTR P02766 1/20 0.35
IL2 P60568 1/20 0.35
TP53 P04637 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11990336 0.92 LMNA (0.42) LMNAMEN1KMT2ACYP2C19CYP3A4
SCHEMBL20434503 0.85 EPHX2 (0.40) LMNAMEN1KMT2ACYP2C19CYP3A4
SCHEMBL19116591 0.84 MEN1 (0.49) LMNAMEN1KMT2ACYP2C19CYP3A4
SCHEMBL19116585 0.84 MEN1 (0.49) LMNAMEN1KMT2ACYP2C19CYP3A4
SCHEMBL14519321 0.83 LMNA (0.38) LMNAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL26712776 0.81 MAPT (0.41) LMNAMEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL12377426 0.80 CTH (0.35) LMNAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11990499 0.79 SMN1; SMN2 (0.53) LMNAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL24285353 0.79 LMNA (0.43) LMNAMEN1KMT2ACYP2C19SMN1; SMN2
SCHEMBL15044600 0.79 SMN1; SMN2 (0.40) LMNAMEN1KMT2ACYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729258-B2 Luminescent macrocyclic lanthanide complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-20 US disclosed
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-12-27 US disclosed
US-8173800-B2 Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-08 US disclosed
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES SSB, HACD3, CLTA LMNA 2003/4885MEN1 1772/4885KMT2A 3655/4885
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES SSB, HACD3, CLTA LMNA 2003/4885MEN1 1772/4885KMT2A 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.